+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Verified

Ovarian Cancer Academy – EarlyCareer Investigator Award

U.S Department of Defense

Summary: Initially created in FY09, the OCRP Ovarian Cancer Academy (OCA) is a unique, interactive virtual academy providing intensive mentoring, national networking, collaborations, and a peer group for junior faculty. The overarching goal of the OCA is to conduct innovative and impactful ovarian cancer research while developing successful, highly productive ovarian cancer researchers in a collaborative research and career development environment.

Distinctive Features: The OCA is a virtual career development and research training platform that consists of Early-Career Investigators (ECIs), their Designated Mentors, and an Academy Dean and Assistant Dean. The OCA-ECI Award is not a traditional career development award; the ECI is expected to participate in monthly webinars and annual workshops and to communicate and collaborate with other members of the Academy (other ECIs, Mentors, the Dean and Assistant Dean) as well as with the advocacy community.

Funding Details: The Congressionally Directed Medical Research Programs (CDMRP) expects to allot roughly $4.5M to fund approximately four Ovarian Cancer Academy – Early-Career Investigator Award applications with total cost caps of $1.125M per award. The maximum period of performance is 4 years. It is anticipated that awards made from this fiscal year 2026 (FY26) funding opportunity will be funded with FY26 funds, which will expire for use on September 30, 2032. Awards supported with FY26 funds will be made no later than September 30, 2027.

AI Based Application Success Predictor

1. Alignment with the specific Program Announcement (PA) (Highest Predictor ⭐⭐⭐⭐⭐)

This is consistently the most important predictor.

Every CDMRP mechanism has unique:

Research priorities
Funding intent
Award level
Eligibility
Innovation expectations
Translational expectations

Successful applicants carefully tailor their proposal to the exact mechanism, not merely the disease area.

Applications that fail to address the mechanism's stated objectives are frequently eliminated regardless of scientific quality.

2. Impact (Highest Predictor ⭐⭐⭐⭐⭐)

Unlike many agencies where scientific excellence dominates, CDMRP places exceptional emphasis on potential impact.

Reviewers ask:

Will this improve patient outcomes?
Will it solve an important clinical problem?
Will it transform current practice?
Will patients benefit?

Impact is frequently weighted as heavily as scientific merit.

Projects with only incremental advances rarely score well.

3. Innovation (Highest Predictor ⭐⭐⭐⭐⭐)

Innovation is one of the defining characteristics of CDMRP.

Highly competitive proposals usually include:

Novel biological concepts
First-in-field technologies
High-risk/high-reward science
AI applications
Precision medicine
Regenerative medicine
Cell therapy
Gene therapy
Novel biomarkers
New therapeutic platforms

Incremental projects are less competitive unless they provide exceptional impact.

4. Scientific Merit (Very High Predictor ⭐⭐⭐⭐⭐)

Reviewers carefully evaluate:

Scientific rationale
Importance of hypothesis
Experimental design
Statistical methods
Preliminary rationale (when appropriate)
Technical rigor

Weak methodology can prevent funding even for highly innovative ideas.

5. Translational Potential (Very High Predictor ⭐⭐⭐⭐⭐)

CDMRP strongly favors research that can move discoveries toward patient care.

Highly competitive proposals include a clear pathway toward:

Diagnostics
Medical devices
Drug development
Biomarkers
Clinical trials
Precision medicine
Clinical implementation

Applications should explain how the research will ultimately improve healthcare.

6. Consumer/Patient Relevance (Very High & Distinctive Predictor ⭐⭐⭐⭐⭐)

This is one of CDMRP's most distinctive features.

Many review panels include:

Patients
Survivors
Caregivers
Consumer advocates

Strong proposals demonstrate:

Patient-centered outcomes
Consumer engagement
Relevance to unmet patient needs
Meaningful improvements in quality of life

Consumer reviewers participate directly in many CDMRP peer-review panels.

7. Military and Veteran Relevance (when applicable) (Very High Predictor ⭐⭐⭐⭐☆)

Although many CDMRP programs serve the general population, reviewers often consider relevance to:

Active-duty personnel
Veterans
Military families
Military readiness
Combat-related conditions

For some programs (e.g., traumatic brain injury, orthopedic trauma, rehabilitation), this relevance is particularly important.

8. Strong Multidisciplinary Team (High Predictor ⭐⭐⭐⭐☆)

Successful applications often include:

Clinicians
Basic scientists
Engineers
Statisticians
Bioinformaticians
Industry collaborators
Patient advocates

Large Team Science awards especially require complementary expertise and integrated collaboration.

9. Feasibility and Project Management (High Predictor ⭐⭐⭐⭐☆)

Competitive applications demonstrate:

Realistic milestones
Risk mitigation
Timeline
Budget justification
Available infrastructure
Institutional resources

Even ambitious projects need credible execution plans.

10. Investigator and Institutional Strength (High Predictor ⭐⭐⭐⭐☆)

Reviewers assess:

Publication record
Previous grant success
Leadership
Relevant expertise
Institutional resources
Available facilities

For Career Development Awards, leadership potential and mentorship are additional strengths.

11. Programmatic Portfolio Fit (Unique CDMRP Predictor ⭐⭐⭐⭐☆)

Unlike NIH, CDMRP conducts a Programmatic Review after peer review.

Programmatic reviewers consider:

Balance across disease areas
Balance across research topics
Funding mechanism priorities
Military needs
Consumer priorities
Existing funded portfolio

A proposal with an excellent scientific score may still not be funded if it duplicates already-funded work or does not fit the current portfolio.

Specialties

Cancer

Oncology

Gynecology

Eligibility Requirements

Organization Extramural and intramural U.S. Department of War (DOW) organizations are eligible to apply, including foreign and domestic organizations, for-profit and nonprofit organizations, and public or private entities.

Principal Investigator Individuals affiliated with an eligible organization are eligible to be named Principal Investigator (PI) on the application, regardless of ethnicity, nationality or citizenship status. Early-Career Investigator

• Must be within five years of last postdoctoral research position (Ph.D.), clinical fellowship (M.D.), or equivalent as of the full application submission deadline. ○ Individuals in a postdoctoral research position (Ph.D.), clinical fellowship (M.D.) or equivalent at the time of full application submission are not eligible. ○ A Statement of Eligibility is required with the submission of the full application.

• May be a research- or physician-scientist.

• May be in a non-tenure track or tenure track position.

• Must not have a concurrent career development-like award at the time of this award.

• Must have an institutional commitment of approximately 50% protected time for ovarian cancer research and OCA activities, including participation in monthly webinars.

○ Must commit no less than 25% effort to this award for the first two years.

• Designated Mentor

○ Must be an independent, established ovarian cancer researcher.

○ Must have ovarian cancer research funding (past and present).

○ Must have a record of ovarian cancer publications in peer-reviewed journals.

○ May be at the same institution as the ECI. If not at the same institution, another mentor (“Other Mentor,” see below) at the ECI’s institution must also be included in the application submission.

○ Must demonstrate a commitment (at least 5% effort for mentoring and participating in OCA activities such as offsite meetings and webinars) to develop and sustain the ECI’s independent career in ovarian cancer research.

○ A current OCA Designated Mentor can only be a Designated Mentor to one OCA-ECI; thus, current OCA Designated Mentors cannot be named as a Designated Mentor in an FY26 application unless the period of performance of the current OCA-ECI Award mechanism ends no later than July 2027. Information about current OCA membership is available through the OCA website.

○ The current OCA Dean and/or Assistant Dean cannot be listed as a Designated Mentor.

• Other Mentor (if applicable)

○ Must be at the same institution as the ECI.

○ Must be an independent cancer researcher but not necessarily in ovarian cancer.

○ Must have research funding (past and present).

Cost Sharing Cost sharing is not an eligibility requirement.

Sponsor Details

Sponsor Institute/Organizations: U.S Department of Defense

Sponsor Type: Corporate/Non-Profit

Address: The Pentagon, Washington, DC 20301

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity